FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916433178> ?p ?o ?g. }

• W2916433178 endingPage "iii44" @default.
• W2916433178 startingPage "iii33" @default.
• W2916433178 abstract "Ceftaroline (active form of the prodrug ceftaroline fosamil) is a novel cephalosporin with activity against pathogens commonly associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and Gram-negative pathogens. This randomized, double-blind, Phase III study evaluated the efficacy and safety of ceftaroline fosamil in treating patients with CAP. The primary objective was to determine non-inferiority [lower limit of 95% confidence interval (CI) ≥ −10%] of clinical cure rates achieved with ceftaroline fosamil compared with those achieved with ceftriaxone in the clinically evaluable (CE) and modified intent-to-treat efficacy (MITTE) populations. Patients hospitalized in a non-intensive care unit setting with CAP of Pneumonia Outcomes Research Team (PORT) risk class III or IV requiring intravenous (iv) therapy were randomized (1:1) to receive 600 mg of ceftaroline fosamil iv every 12 h or 1 g of ceftriaxone iv every 24 h. Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed. FOCUS 2 registration number NCT00509106 (http://clinicaltrials.gov/ct2/show/NCT00509106). The study enrolled 627 patients, 315 of whom received ceftaroline fosamil and 307 of whom received ceftriaxone. Patients in both treatment groups had comparable baseline characteristics. Clinical cure rates were as follows: CE population, 82.1% (193/235) for ceftaroline fosamil and 77.2% (166/215) for ceftriaxone [difference (95% CI), 4.9% (−2.5, 12.5)]; and MITTE population, 81.3% (235/289) for ceftaroline fosamil and 75.5% (206/273) for ceftriaxone [difference (95% CI), 5.9% (−1.0, 12.7)]. Clinical cure rates for CAP caused by S. pneumoniae in the microbiological MITTE (mMITTE) population were 83.3% (35/42) and 70.0% (28/40) for ceftaroline fosamil and ceftriaxone, respectively. Ceftaroline fosamil and ceftriaxone were well tolerated, with similar rates of AEs, serious AEs, deaths and discontinuations due to an AE. The most common AEs for ceftaroline fosamil-treated patients were diarrhoea, headache, hypokalaemia, insomnia and phlebitis, and the most common AEs for ceftriaxone-treated patients were diarrhoea, insomnia, phlebitis and hypertension. Ceftaroline fosamil achieved high clinical cure and microbiological response rates in patients hospitalized with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile that is similar to that of ceftriaxone and other cephalosporins. Ceftaroline fosamil is a promising agent for the treatment of CAP." @default.
• W2916433178 created "2019-03-02" @default.
• W2916433178 creator A5000452842 @default.
• W2916433178 creator A5002308203 @default.
• W2916433178 creator A5002369396 @default.
• W2916433178 creator A5003106729 @default.
• W2916433178 creator A5003345532 @default.
• W2916433178 creator A5008776510 @default.
• W2916433178 creator A5009057350 @default.
• W2916433178 creator A5009176504 @default.
• W2916433178 creator A5009910681 @default.
• W2916433178 creator A5011121666 @default.
• W2916433178 creator A5012062102 @default.
• W2916433178 creator A5012927597 @default.
• W2916433178 creator A5013312292 @default.
• W2916433178 creator A5013439448 @default.
• W2916433178 creator A5013585746 @default.
• W2916433178 creator A5014452440 @default.
• W2916433178 creator A5014628070 @default.
• W2916433178 creator A5016729678 @default.
• W2916433178 creator A5018050182 @default.
• W2916433178 creator A5019583794 @default.
• W2916433178 creator A5020912810 @default.
• W2916433178 creator A5022473719 @default.
• W2916433178 creator A5024117953 @default.
• W2916433178 creator A5024575899 @default.
• W2916433178 creator A5025497749 @default.
• W2916433178 creator A5025547431 @default.
• W2916433178 creator A5026303511 @default.
• W2916433178 creator A5027304622 @default.
• W2916433178 creator A5028147913 @default.
• W2916433178 creator A5029139734 @default.
• W2916433178 creator A5029438815 @default.
• W2916433178 creator A5030138293 @default.
• W2916433178 creator A5030256873 @default.
• W2916433178 creator A5030290228 @default.
• W2916433178 creator A5030300573 @default.
• W2916433178 creator A5030358055 @default.
• W2916433178 creator A5030458607 @default.
• W2916433178 creator A5030596526 @default.
• W2916433178 creator A5030819418 @default.
• W2916433178 creator A5030957826 @default.
• W2916433178 creator A5031196682 @default.
• W2916433178 creator A5031211495 @default.
• W2916433178 creator A5031373908 @default.
• W2916433178 creator A5031410837 @default.
• W2916433178 creator A5031780287 @default.
• W2916433178 creator A5031817317 @default.
• W2916433178 creator A5031943143 @default.
• W2916433178 creator A5032642785 @default.
• W2916433178 creator A5032752465 @default.
• W2916433178 creator A5033794105 @default.
• W2916433178 creator A5033860654 @default.
• W2916433178 creator A5035800223 @default.
• W2916433178 creator A5036142997 @default.
• W2916433178 creator A5036591050 @default.
• W2916433178 creator A5036987407 @default.
• W2916433178 creator A5037210897 @default.
• W2916433178 creator A5040064524 @default.
• W2916433178 creator A5040952607 @default.
• W2916433178 creator A5041959529 @default.
• W2916433178 creator A5042277134 @default.
• W2916433178 creator A5042520277 @default.
• W2916433178 creator A5044283478 @default.
• W2916433178 creator A5044422796 @default.
• W2916433178 creator A5044810746 @default.
• W2916433178 creator A5045694041 @default.
• W2916433178 creator A5047984943 @default.
• W2916433178 creator A5048094805 @default.
• W2916433178 creator A5048320943 @default.
• W2916433178 creator A5048572356 @default.
• W2916433178 creator A5048767520 @default.
• W2916433178 creator A5048800164 @default.
• W2916433178 creator A5049710711 @default.
• W2916433178 creator A5050568491 @default.
• W2916433178 creator A5052394021 @default.
• W2916433178 creator A5052734473 @default.
• W2916433178 creator A5052793498 @default.
• W2916433178 creator A5053400330 @default.
• W2916433178 creator A5053593162 @default.
• W2916433178 creator A5054829461 @default.
• W2916433178 creator A5055446548 @default.
• W2916433178 creator A5056291766 @default.
• W2916433178 creator A5057241591 @default.
• W2916433178 creator A5057751016 @default.
• W2916433178 creator A5058653363 @default.
• W2916433178 creator A5059387153 @default.
• W2916433178 creator A5059988332 @default.
• W2916433178 creator A5060750925 @default.
• W2916433178 creator A5060766311 @default.
• W2916433178 creator A5061089842 @default.
• W2916433178 creator A5061937985 @default.
• W2916433178 creator A5062343173 @default.
• W2916433178 creator A5063814702 @default.
• W2916433178 creator A5063962901 @default.
• W2916433178 creator A5064450877 @default.
• W2916433178 creator A5066680735 @default.
• W2916433178 creator A5066696595 @default.

• next